We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

PRPO:NASDAQPrecipio, Inc. Analysis

Data as of 2026-04-25 - not real-time

$28.00

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Precipio, Inc. (PRPO) is trading near the upper end of its 20‑day SMA ($27.18) and above both its 50‑day ($26.36) and 200‑day ($21.47) averages, suggesting a short‑term bullish bias. However, the MACD histogram has turned negative (-0.095) and the RSI sits at a neutral 53, while volume is trending down, indicating weakening momentum as the stock approaches its technical resistance around $29.80. The company posted strong top‑line growth (22.9% YoY revenue increase to $24M) and achieved positive operating cash flow in 2025, highlighted in recent earnings call transcripts, and even saw insider buying (COO purchased shares at $27.93). Despite these operational improvements, valuation metrics remain stretched: the forward PE of 71.8 far exceeds the industry average of 25.4, and a DCF‑derived fair value of $3.45 is dramatically below the current price of $27.99, flagging a severe overvaluation risk.
Given the high 30‑day volatility (≈65%), low beta (~0.33), and a lack of dividend, the stock presents a mixed picture—promising fundamentals counterbalanced by technical softness and an inflated market price. Investors should weigh the upside from continued cash‑flow generation against the downside risk of a valuation correction.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 6/10

Key Factors

  • Technical momentum turning bearish (negative MACD histogram, decreasing volume)
  • Price near resistance with limited upside
  • Severe valuation gap (price far above DCF fair value)

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Sustained revenue growth and positive cash flow generation
  • Insider confidence reflected by recent COO share purchase
  • Valuation still elevated but potential for price stabilization

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Long‑term growth prospects in cancer diagnostics market
  • Improving operating margins and cash conversion
  • Risk that valuation correction may offset upside from fundamentals

Key Metrics & Analysis

Financial Health

Revenue Growth22.90%
Profit Margin-1.51%
P/E Ratio71.8
ROE-2.72%
ROA-3.92%
Debt/Equity25.09
P/B Ratio3.4
Op. Cash Flow$685.0K
Free Cash Flow$210.1K
Industry P/E25.4

Technical Analysis

TrendBullish
RSI53.3
Support$23.70
Resistance$29.80
MA 20$27.18
MA 50$26.36
MA 200$21.47
MACDBearish
VolumeDecreasing
Fear & Greed Index88.02

Valuation

Fair Value$3.45
GradeOvervalued
TypeGrowth

Risk Assessment

Beta0.33
Volatility65.49%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.